Cargando…

The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit

INTRODUCTION: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both. The clinical outcomes of continued...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohl, David A., Kendall, Michelle A., Feinberg, Judith, Alston-Smith, Beverly, Owens, Susan, Chafey, Suzette, Marco, Michael, Maxwell, Sharon, Benson, Constance, Keiser, Philip, van der Horst, Charles, Jacobson, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829816/
https://www.ncbi.nlm.nih.gov/pubmed/24260125
http://dx.doi.org/10.1371/journal.pone.0078676
_version_ 1782291395175776256
author Wohl, David A.
Kendall, Michelle A.
Feinberg, Judith
Alston-Smith, Beverly
Owens, Susan
Chafey, Suzette
Marco, Michael
Maxwell, Sharon
Benson, Constance
Keiser, Philip
van der Horst, Charles
Jacobson, Mark A.
author_facet Wohl, David A.
Kendall, Michelle A.
Feinberg, Judith
Alston-Smith, Beverly
Owens, Susan
Chafey, Suzette
Marco, Michael
Maxwell, Sharon
Benson, Constance
Keiser, Philip
van der Horst, Charles
Jacobson, Mark A.
author_sort Wohl, David A.
collection PubMed
description INTRODUCTION: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both. The clinical outcomes of continued ART prescription for such patients have not been well characterized. METHODS: We examined the causes and predictors of all-cause mortality, AIDS-defining conditions, and serious non-AIDS-defining events among a cohort of participants in a clinical trial of pre-emptive therapy for CMV disease. We focused on participants who, despite ART had failed to achieve virologic suppression and substantive immune reconstitution. RESULTS: 233 ART-receiving participants entered with a median baseline CD4+ T cell count of 30/mm(3) and plasma HIV RNA of 5 log(10) copies/mL. During a median 96 weeks of follow-up, 24.0% died (a mortality rate of 10.7/100 patient-years); 27.5% reported a new AIDS-defining condition, and 22.3% a new serious non-AIDS event. Of the deaths, 42.8% were due to an AIDS-defining condition, 44.6% were due to a non-AIDS-defining condition, and 12.5% were of unknown etiology. Decreased risk of mortality was associated with baseline CD4+ T cell count ≥25/mm(3) and lower baseline HIV RNA. CONCLUSIONS: Among patients with advanced AIDS prescribed modern ART who achieve neither virologic suppression nor immune reconstitution, crude mortality percentages appear to be lower than reported in cohorts of patients studied a decade earlier. Also, in contrast to the era before modern ART became available, nearly half of the deaths in our modern-era study were caused by serious non-AIDS-defining events. Even among the most advanced AIDS patients who were not obtaining apparent immunologic and virologic benefit from ART, continued prescription of these medications appears to alter the natural history of AIDS—improving survival and shifting the causes of death from AIDS- to non-AIDS-defining conditions.
format Online
Article
Text
id pubmed-3829816
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38298162013-11-20 The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit Wohl, David A. Kendall, Michelle A. Feinberg, Judith Alston-Smith, Beverly Owens, Susan Chafey, Suzette Marco, Michael Maxwell, Sharon Benson, Constance Keiser, Philip van der Horst, Charles Jacobson, Mark A. PLoS One Research Article INTRODUCTION: Despite the efficacy and tolerability of modern antiretroviral therapy (ART), many patients with advanced AIDS prescribed these regimens do not achieve viral suppression or immune reconstitution as a result of poor adherence, drug resistance, or both. The clinical outcomes of continued ART prescription for such patients have not been well characterized. METHODS: We examined the causes and predictors of all-cause mortality, AIDS-defining conditions, and serious non-AIDS-defining events among a cohort of participants in a clinical trial of pre-emptive therapy for CMV disease. We focused on participants who, despite ART had failed to achieve virologic suppression and substantive immune reconstitution. RESULTS: 233 ART-receiving participants entered with a median baseline CD4+ T cell count of 30/mm(3) and plasma HIV RNA of 5 log(10) copies/mL. During a median 96 weeks of follow-up, 24.0% died (a mortality rate of 10.7/100 patient-years); 27.5% reported a new AIDS-defining condition, and 22.3% a new serious non-AIDS event. Of the deaths, 42.8% were due to an AIDS-defining condition, 44.6% were due to a non-AIDS-defining condition, and 12.5% were of unknown etiology. Decreased risk of mortality was associated with baseline CD4+ T cell count ≥25/mm(3) and lower baseline HIV RNA. CONCLUSIONS: Among patients with advanced AIDS prescribed modern ART who achieve neither virologic suppression nor immune reconstitution, crude mortality percentages appear to be lower than reported in cohorts of patients studied a decade earlier. Also, in contrast to the era before modern ART became available, nearly half of the deaths in our modern-era study were caused by serious non-AIDS-defining events. Even among the most advanced AIDS patients who were not obtaining apparent immunologic and virologic benefit from ART, continued prescription of these medications appears to alter the natural history of AIDS—improving survival and shifting the causes of death from AIDS- to non-AIDS-defining conditions. Public Library of Science 2013-11-15 /pmc/articles/PMC3829816/ /pubmed/24260125 http://dx.doi.org/10.1371/journal.pone.0078676 Text en © 2013 Wohl et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wohl, David A.
Kendall, Michelle A.
Feinberg, Judith
Alston-Smith, Beverly
Owens, Susan
Chafey, Suzette
Marco, Michael
Maxwell, Sharon
Benson, Constance
Keiser, Philip
van der Horst, Charles
Jacobson, Mark A.
The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
title The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
title_full The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
title_fullStr The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
title_full_unstemmed The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
title_short The Clinical Impact of Continuing to Prescribe Antiretroviral Therapy in Patients with Advanced AIDS Who Manifest No Virologic or Immunologic Benefit
title_sort clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced aids who manifest no virologic or immunologic benefit
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829816/
https://www.ncbi.nlm.nih.gov/pubmed/24260125
http://dx.doi.org/10.1371/journal.pone.0078676
work_keys_str_mv AT wohldavida theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT kendallmichellea theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT feinbergjudith theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT alstonsmithbeverly theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT owenssusan theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT chafeysuzette theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT marcomichael theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT maxwellsharon theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT bensonconstance theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT keiserphilip theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT vanderhorstcharles theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT jacobsonmarka theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT theclinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT wohldavida clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT kendallmichellea clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT feinbergjudith clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT alstonsmithbeverly clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT owenssusan clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT chafeysuzette clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT marcomichael clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT maxwellsharon clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT bensonconstance clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT keiserphilip clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT vanderhorstcharles clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT jacobsonmarka clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit
AT clinicalimpactofcontinuingtoprescribeantiretroviraltherapyinpatientswithadvancedaidswhomanifestnovirologicorimmunologicbenefit